Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Puma Biotech's lawsuit against AstraZeneca progresses

EditorNatashya Angelica
Published 03/19/2024, 04:35 PM
© Reuters.

In a significant development, the legal battle between Puma Biotechnology Inc. (NASDAQ: NASDAQ:PBYI) and AstraZeneca (NASDAQ: NASDAQ:AZN) over alleged patent infringement has seen recent court decisions. The dispute centers around the accusation that AstraZeneca's cancer drug Tagrisso® infringes on two patents held by Puma Biotech.

The patents in question, United States Patent Nos. 10,603,314 and 10,596,162, relate to treatments for non-small cell lung cancer resistant to certain drugs. Puma Biotech claims that AstraZeneca's manufacture and sale of Tagrisso® infringe these patents. Puma is an exclusive licensee under the Pfizer Agreement, which includes the '314 and '162 patents.

On Monday, the court made several rulings affecting the case's trajectory. AstraZeneca's motions to prove the patents invalid and for summary judgment of non-infringement were denied. However, the court did rule in AstraZeneca's favor regarding pre-issuance damages. The court also dismissed motions to exclude specific expert testimonies from both parties.

Furthermore, AstraZeneca's attempt to dismiss Puma Biotech and co-plaintiff Wyeth from the lawsuit was partially successful. The court ruled that Puma Biotech lacked constitutional standing and was dismissed as a plaintiff, although it remains a counterclaim-defendant. Conversely, Wyeth's standing as a plaintiff was upheld.

Despite this setback for Puma Biotech, the company retains its contractual rights to recover monetary damages from the litigation, as per its license agreement with Pfizer Inc. (NYSE:PFE), Wyeth's parent company. These rights are not affected by the court's decision on the standing motion.

The case is set to continue, with a jury trial scheduled for May 13, 2024. This ongoing litigation is closely watched by industry observers, as it involves a high-profile cancer treatment and could have significant financial implications for the companies involved.

This report is based on an 8K filing with the SEC and reflects the latest available information on the legal proceedings between Puma Biotechnology and AstraZeneca.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.